Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
SAN DIEGO, May 31, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present at the Jefferies 2017 Healthcare Conference at 4:00 pm EDT on Wednesday, June 7, 2017, in New York, NY.
To access a live webcast of the presentation, please visit the “Events and Presentation” section within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com. A replay of the webcast will be available on the website for 60 days following the event.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma; and TRC253, a small molecule that is being developed for the treatment of prostate cancer. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected] Company Contact: Casey Logan Chief Business Officer (858) 550‐0780 ext. 236 [email protected]
